The data show the use of IBM to deliver the anti-CD40 significantly enhances the effectiveness of in situ vaccination with anti-CD40 compared with direct injection (Figure 3A) in pancreatic (Figures 3A, B, p < 0.001) and prostate cancers (Figure 3C, p < 0.0001) with increase survival with p < 0.01 and p < 0.001, respectively (Figure 3D). This evidence concerns the gene CD40 and prostate carcinoma.